Published in

American Society of Hematology, Blood Advances, 12(1), p. 753-765, 2017

DOI: 10.1182/bloodadvances.2017004382

Links

Tools

Export citation

Search in Google Scholar

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models

Journal article published in 2017 by Natalie A. Bezman, Amy Jhatakia, Alper Y. Kearney, Ty Brender, Mark Maurer, Karla Henning, Misty R. Jenkins ORCID, Amy J. Rogers, Paul J. Neeson, Alan J. Korman, Michael D. Robbins, Robert F. Graziano
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Key PointsThe combination of elotuzumab and an anti–PD-1 antibody leads to enhanced antitumor efficacy in mouse models. Enhanced antitumor activity is likely due to the promotion of tumor-infiltrating NK and T-cell activity.